A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Registration

Registration

NCT05815680

Study type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Phase

PHASE1

Masking

NONE

Status

COMPLETED

Enrollment

48

Start

2023-04-06

Primary completion

2023-08-18

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Overweight Subjects; Obese Subjects

Interventions

DRUG:metformin; DRUG:digoxin; DRUG:IBI362; DRUG:warfarin; DRUG:atorvastatin

Results posted

FALSE

Registered primary outcomes

• Maximum observed metformin plasma concentration at steady state [up to 116 days]
• Area under the metformin plasma concentration-time curve [up to 116 days]
• Maximum observed warfarin plasma concentration at steady state [up to 116 days]
• Area under the warfarin plasma concentration-time curve [up to 116 days]
• Maximum observed atorvastatin plasma concentration at steady state [up to 116 days]
• Area under the atorvastatin plasma concentration-time curve [up to 116 days]
• Maximum observed digoxin plasma concentration at steady state [up to 116 days]
• Area under the digoxin plasma concentration-time curve [up to 116 days]